<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088060</url>
  </required_header>
  <id_info>
    <org_study_id>CBD-FEP</org_study_id>
    <secondary_id>2012-004335-23</secondary_id>
    <nct_id>NCT02088060</nct_id>
  </id_info>
  <brief_title>A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients</brief_title>
  <official_title>A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Institute of Mental Health, Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Martin-Luther-Universität Halle-Wittenberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Institute of Mental Health, Mannheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Schizophrenia is a heterogeneous mental disorder that affects one percent of the world's
      population. Current antipsychotics are only partially effective, and their use is often
      associated with serious side effects. Cannabidiol is a natural counterpart of the
      psychoactive component of marijuana, delta-9-tetrahydrocannabinol. While cannabidiol has no
      psychotomimetic or addictive properties, it indirectly affects endogenous cannabinoid
      signalling by impairing the degradation of the endocannabinoid anandamide. In a controlled
      clinical trial of cannabidiol versus amisulpride (an established antipsychotic) in acute
      paranoid schizophrenics the investigators showed a significant clinical improvement in all
      symptoms of schizophrenia compared to baseline with either treatment. But cannabidiol
      displayed a significantly superior side-effect profile. This study is to evaluate the
      efficacy and safety of this novel treatment option in comparison to placebo and olanzapine,
      an established second generation antipsychotic in the treatment of acute schizophrenia and
      schizophrenia maintenance therapy, in a four-week clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Positive and Negative Syndrome Scale (PANSS) total score</measure>
    <time_frame>within 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the PANSS subscores and clusters</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Clinical Global Impression score</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Global Assessment of Functioning Scale</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Personal and Social Performance Scale</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Calgary Depression Scale for Schizophrenia</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Hamilton Anxiety Scale</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive skills</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to antipsychotic medication</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of endogenous cannabinoids</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in physiological parameter</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the UKU Side Effect Rating Scale</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicidality Severity Rating Scale</measure>
    <time_frame>within 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cannabidiol capsules 2x200 mg twice a day and placebo olanzapine capsule once a day over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine capsule 15mg once a day and placebo cannabidiol capsules twice a day over 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cannabidiol capsules twice a day and placebo olanzapine capsule once a day over 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Cannabidiol capsules</description>
    <arm_group_label>Cannabidiol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine capsules</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Olanzapine 1A pharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cannabidiol</intervention_name>
    <description>Placebo cannabidiol capsules</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Olanzapine</intervention_name>
    <description>Placebo olanzapine capsules</description>
    <arm_group_label>Cannabidiol</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent given by the subject

          -  DSM-IV-TR diagnosis of schizophrenic psychosis (295.10, 295.20, 295.30, 295.90
             (American Psychiatric Association)

          -  Patients must be within the first three years of illness, i.e. first diagnosis of
             schizophrenia is no older than three years.

          -  Age 18 to 65 years, male or female

          -  Minimal initial PANSS score of 75 at baseline

          -  Female patients of childbearing potential need to utilize a proper method of
             contraception.

          -  Body Mass Index between 18 and 40

        Exclusion Criteria:

          -  Lack of accountability (assessed by an independent psychiatrist)

          -  History of treatment-resistant schizophrenia, defined as no response to at least two
             antipsychotics given for a minimum of 6 weeks each in an adequate dosage

          -  Positive urine drug-screening for illicit drugs at screening (except cannabinoids and
             benzodiazepines)

          -  Serious suicidal risk at screening visit (Subject to investigator's and independent
             psychiatrist's judgement: Poses a serious suicidal or homicidal risk at screening
             visit or has made a serious suicide attempt within the last 12 months prior to
             screening visit, or has exhibited homicidal behaviour at anytime during her/his
             lifetime)

          -  Known intolerance or allergy to olanzapine or cannabidiol

          -  Other relevant interferences of axis 1 (e.g. serious depression) according to
             diagnostic evaluation (MINI) including residual forms of schizophrenia

          -  Pregnancy, as determined through a β-HCG pregnancy test, or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>F. Markus Leweke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Institute of Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Centre Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of General Psychiatry, Heidelberg University</name>
      <address>
        <city>Heidelberg</city>
        <state>BW</state>
        <zip>68115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dep. of Psychiatry and Psychotherapy, Central Institute of Mental Health</name>
      <address>
        <city>Mannheim</city>
        <state>BW</state>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Ludwig-Maximillians-University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Technical University Munich</name>
      <address>
        <city>Munich</city>
        <state>BY</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Psychiatry and Psychotherapy, Martin-Luther-University, Halle/Wittenberg</name>
      <address>
        <city>Halle</city>
        <state>Saint</state>
        <zip>06112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2014</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

